MINI REVIEW article
Front. Pharmacol.
Sec. Experimental Pharmacology and Drug Discovery
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1691119
This article is part of the Research TopicAdvances in the Use of Computational Methods in the Design of Targeted Pleiotropic DrugsView all articles
The Computationally Guided Design of Selective Targeters of Multiple Proteins (STaMPs) as a New Opportunity for Small Molecule Drug Discovery
Provisionally accepted
- Avicenna Biosciences, Inc., Durham, NC, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Polypharmacology has long been an aspect of drug design for small molecules, and the multi-target pursuit has frequently behaved more akin to divine chance rather than controllable science. Targets unknown or once thought undesirable can often be revealed to be key points of intervention for the positive effects of a drug later in the development of a program or even after its approval. In this review, we look at historical examples of molecular pleiotropism and evaluate how new insights from computational systems biology and small molecule design can aid the rational design of Selective Targeters of Multiple Proteins (STaMPs).
Keywords: Synthetic Biology, drug design, polypharmacology, Computational drug design, machine learning, Systems Biology, Medicinal Chemistry, Pleiotropism
Received: 22 Aug 2025; Accepted: 25 Sep 2025.
Copyright: © 2025 Kaiser. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Thomas M Kaiser, tkaiser@avicenna-bio.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.